Market revenue in 2024 | USD 1,822.0 million |
Market revenue in 2030 | USD 3,701.6 million |
Growth rate | 12.8% (CAGR from 2025 to 2030) |
Largest segment | Circulating cell free dna (ccfdna) |
Fastest growing segment | Circulating Cell Free RNA (ccfRNA) / miRNA |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA |
Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 39.52% in 2024. Horizon Databook has segmented the Italy rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of labs, such as GENOMA GROUP laboratories, that perform PrenatalSAFE Karyo, an NIPT, i s anticipated to positively impact the revenue growth i n the country. Furthermore, several initiatives are being undertaken to advance the use of liquid biopsy tests i n this country. In March 2019, MDxHealth SA’s SelectMDx liquid biopsy test, which i s developed for detection of prostate cancer was included i n the 2019 Italian Society of Urology (SIU) guidelines. This achievement i s expected to boost the use of SelectMDx i n this country. This, i n turn, would directly impact the sales of rare biomarker isolation kits i n the country
Horizon Databook provides a detailed overview of country-level data and insights on the Italy rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This country databook contains high-level insights into Italy rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account